awmsg logo



daratumumab (Darzalex®)


Reference No. 2834

Publication date:
30/09/2016


Appraisal information

daratumumab (Darzalex®) 20 mg/ml concentrate for solution for infusion


Company: Janssen-Cilag Ltd
BNF category: Malignant disease and immunosupression
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
   
   
Submission Type: Nonsubmission
Status: Not endorsed
Advice No: Not available
Ratification by Welsh Government: 29/09/2016

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

In the absence of a submission from the holder of the marketing authorisation, daratumumab (Darzalex®) cannot be endorsed for use within NHS Wales as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, whose prior therapy included a proteasome inhibitor and an immunomodulatory agent and who have demonstrated disease progression on the last therapy.
Statement of Advice (SOA)
Download